Organoids are tiny, self-organized, three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ or to express selected aspects of it, like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters.
Key driving factors include the factors driving organoids market growth are the growing adoption of personalized drugs. Increasing demand for tumor modeling and biobanking. However, issues related to the incorporation of organoids into existing workflows and the dearth of skilled professionals hinder organoids market growth.
The organoids market is majorly comprised of top players involving STEMCELL Technologies Inc; Cellesce Ltd; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; PeproTech, Inc; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA, and InSphero. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.